Maxim Group Reiterates Sell on Momenta (MNTA)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Momenta Phama (MNTA) Resumes Enrollment in M402 Combo Phase 2
December 21, 2015 8:04 AM ESTMomenta Pharmaceuticals, Inc. (NASDAQ: MNTA) announced that it has resumed patient enrollment in its ongoing Phase 2 portion of the trial A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination with nab-Paclitaxel and Gemcitabine in Patients with Metastatic... More
Momenta Phama (MNTA), Baxalta (BXLT) ANnounce M923 Met Primary Endpoint vs. HUMIRA
December 21, 2015 6:47 AM ESTBaxalta Incorporated (NYSE: BXLT) and Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), announced that M923 met the primary endpoint in a randomized, double-blind, three-arm, parallel group, single-dose study. The primary objective of the study was to evaluate the pharmacokinetics of M923 compared to both U.S. and EU sourced HUMIRA® reference products.
We are encouraged by the results of this study, said John Orloff, M.D., head of Research &... More
